LB Pharmaceuticals (LBRX) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases.

• Lead product candidate, LB-102, is a Phase 3-ready oral small molecule designed as a methylated derivative of amisulpride, aiming for improved efficacy and tolerability.

• LB-102 targets D2, D3, and 5HT7 receptors, with potential applications in schizophrenia, bipolar depression, and other neuropsychiatric disorders.

• Pipeline includes plans for long-acting injectable (LAI) formulations and expansion into additional indications such as major depressive disorder and Alzheimer’s-related psychosis.

Financial performance and metrics

• No product revenue to date; operations funded primarily through equity and convertible note financings.

• Net loss of $63.1 million for the year ended December 31, 2024, and $10.2 million for the six months ended June 30, 2025.

• Accumulated deficit of $114.5 million as of June 30, 2025.

• Cash and cash equivalents of $14.2 million as of June 30, 2025.

• Research and development expenses were $51.2 million in 2024, primarily due to Phase 2 clinical trial costs.

Use of proceeds and capital allocation

• Net proceeds from the IPO, together with existing cash, will be used to advance clinical development of LB-102 for acute schizophrenia (Phase 3) and bipolar depression (Phase 2), with the remainder for general corporate purposes.

• May allocate a portion of proceeds to in-license, acquire, or invest in complementary businesses or technologies.

• Proceeds are not sufficient to fund LB-102 through regulatory approval and commercialization; additional capital will be required.